. 2009 Jun 2;90(2):429–437. doi: 10.3945/ajcn.2009.27491

TABLE 2.

Relative risks (RRs) and 95% CIs of type 2 diabetes by randomized antioxidant intervention group in the Women's Antioxidant Cardiovascular Study

	Vitamin C				Vitamin E				β-Carotene
	No. of events¹				No. of events¹				No. of events¹
	Active (n = 3278)	Placebo (n = 3296)	RR (95% CI)	P	Active (n = 3297)	Placebo (n = 3277)	RR (95% CI)	P	Active (n = 3284)	Placebo (n = 3290)	RR (95% CI)	P
Follow-up interval
1–2 y	74	71	1.05 (0.76, 1.45)	0.77	77	68	1.12 (0.81, 1.56)	0.48	66	79	0.84 (0.61, 1.16)	0.29
3–5 y	156	176	0.90 (0.72, 1.12)	0.33	169	163	1.03 (0.83, 1.28)	0.76	168	164	1.02 (0.83, 1.27)	0.84
0–5 y	230	247	0.94 (0.79, 1.13)	0.52	246	231	1.06 (0.89, 1.27)	0.52	234	243	0.96 (0.81, 1.15)	0.68
>5 y	190	228	0.84 (0.69, 1.01)	0.07	228	190	1.21 (1.00, 1.47)	0.05	207	211	0.98 (0.81, 1.19)	0.87
Total follow-up period	420	475	0.89 (0.78, 1.02)	0.09	474	421	1.13 (0.99, 1.29)	0.07	441	454	0.97 (0.85, 1.11)	0.68
Sensitivity analyses excluding first 2 y²	346	404	0.86 (0.75, 1.00)	0.04	397	353	1.13 (0.98, 1.30)	0.10	375	375	1.00 (0.87, 1.16)	0.98
Compliance analyses³	240	247	0.94 (0.79, 1.12)	0.49	243	221	1.17 (0.97, 1.40)	0.10	264	261	1.01 (0.85, 1.20)	0.92

The number of cases of type 2 diabetes.

Excluding those cases occurring in the first 2 y of follow-up.

Analyses restricted to those who reported taking at least two-thirds of the study pills and did not use outside antioxidant supplements containing study agents.